The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.
Ubrelvy is an oral calcitonin gene-related peptide receptor antagonist now approved for the treatment of acute migraines, an FDA press announcement reported. The grant was awarded to Allergan USA, Inc. In clinical trials conducted on over 1,400, the medication was found to be effective in the quick treatment of migraine.